IDSA AMR Guidance — IDSA Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections

A living, question-based guidance document (most recent version 2026) covering ESBL-E, AmpC-E, carbapenem-resistant Enterobacterales, difficult-to-treat-resistance Pseudomonas aeruginosa, carbapenem-resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia — generally preferring newer beta-lactam/beta-lactamase-inhibitor combinations or cefiderocol over older salvage agents (e.g. polymyxins) for carbapenem-resistant infections outside the urinary tract.